In lenvatinib-resistant PTC, notable differences were also observed in cancer fibroblast growth factors and their receptors (FGF1, FGF5, FGF11, FGF13, FGF16, FGFR2, FGFR3, and FGFR4), and additional EMT markers [zinc finger protein SNAIL1 (SNAIL1), SNAIL2, zinc finger E-box-binding homeobox 1 (ZEB1), ZEB2, and twist family bHLH transcription factor 1 (TWIST1)] (Figure 1B, middle and bottom). This evidence concerns the gene FGF13 and cancer.